Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dihydrocodeine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 12/20 | 0.77 |
| ▸ | OPRD1 | P41143 | 12/20 | 0.77 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.74 |
| ▸ | MRGPRX2 | Q96LB1 | 3/20 | 0.66 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.66 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.66 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dihydrocodeine SCHEMBL12402838 | 1.00 | OPRM1 (0.77) | OPRM1OPRD1OPRK1MRGPRX2PDE4D | |
| Dihydrocodeine SCHEMBL13380391 | 1.00 | OPRM1 (0.77) | OPRM1OPRD1OPRK1MRGPRX2PDE4D | |
| Dihydrocodeine SCHEMBL18569649 | 1.00 | OPRM1 (0.77) | OPRM1OPRD1OPRK1MRGPRX2PDE4D | |
| Dihydrocodeine SCHEMBL12960899 | 1.00 | OPRM1 (0.77) | OPRM1OPRD1OPRK1MRGPRX2PDE4D | |
| Dihydrocodeine SCHEMBL159237 | 1.00 | OPRM1 (0.77) | OPRM1OPRD1OPRK1MRGPRX2PDE4D | |
| Dihydrocodeine SCHEMBL12402837 | 1.00 | OPRM1 (0.77) | OPRM1OPRD1OPRK1MRGPRX2PDE4D | |
| Dihydrocodeine SCHEMBL6064584 | 1.00 | OPRM1 (0.77) | OPRM1OPRD1OPRK1MRGPRX2PDE4D | |
| Dihydrocodeine SCHEMBL6123622 | 1.00 | OPRM1 (0.77) | OPRM1OPRD1OPRK1MRGPRX2PDE4D | |
| Dihydrocodeine SCHEMBL19615457 | 1.00 | OPRM1 (0.77) | OPRM1OPRD1OPRK1MRGPRX2PDE4D | |
| Dihydrocodeine SCHEMBL14516219 | 1.00 | OPRM1 (0.77) | OPRM1OPRD1OPRK1MRGPRX2PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190046523-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS | 2019-02-14 | — | — | US | disclosed |
| US-9827239-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2017-11-28 | — | — | US | disclosed |
| US-20170112826-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS | 2017-04-27 | — | — | US | disclosed |
| EP-2628489-B1 | PEG oligomer-fentanyl conjugates | NEKTAR THERAPEUTICS (US) | 2017-03-01 | — | — | EP | disclosed |
| US-9512135-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2016-12-06 | — | — | US | disclosed |
| US-9233168-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2016-01-12 | — | — | US | disclosed |
| US-20150112069-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS | 2015-04-23 | — | — | US | disclosed |
| US-8952032-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2015-02-10 | — | — | US | disclosed |
| US-8575196-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2013-11-05 | — | — | US | disclosed |
| EP-2628489-A1 | PEG oligomer-fentanyl conjugates | Nektar Therapeutics (US) | 2013-08-21 | — | — | EP | disclosed |
| EP-2189460-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 6-ALPHA-HYDROXY-N-ALKYLATED OPIATES | Mallinckrodt Inc. (US) | 2010-05-26 | — | — | EP | disclosed |
| US-20100113788-A1 | Process for the Preparation of 6-Alpha-Hydroxy-N-Alkylated Opiates | MALLINCKRODT INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113788-A1 | Process for the Preparation of 6-Alpha-Hydroxy-N-Alkylated Opiates | MALLINCKRODT INC. (US) | 2010-05-06 | — | — | US | disclosed |
| EP-2180000-A1 | Improved process for the preparation of 6-alpha-hydroxy-n-alkylated opiates | Mallinckrodt Inc. (US) | 2010-04-28 | — | — | EP | disclosed |
| US-20100041888-A1 | Process for the Preparation of 6-Alpha-Hydroxy-N-Alkylated Opiates | MALLINCKRODT ENTERPRISES LLC | 2010-02-18 | — | — | US | disclosed |
| US-20100041888-A1 | Process for the Preparation of 6-Alpha-Hydroxy-N-Alkylated Opiates | MALLINCKRODT ENTERPRISES LLC | 2010-02-18 | — | — | US | disclosed |
| WO-2008137672-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 6-ALPHA-HYDROXY-N-ALKYLATED OPIATES | MALLINCKRODT INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| EP-1810973-A1 | 6-monoacetylmorphine derivatives useful in immunoassay | Roche Diagnostics GmbH (DE) | 2007-07-25 | — | — | EP | disclosed |
| US-7238791-B1 | 6-monoacetylmorphine derivatives useful in immunoassay | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-20070142628-A1 | 6-Monoacetylmorphine derivatives useful in immunoassay | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112826-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | OPRM1, OPRL1, OPRK1 | OPRM1 1/4885OPRD1 5/4885OPRK1 3/4885 |
| US-20100113788-A1 | Process for the Preparation of 6-Alpha-Hydroxy-N-Alkylated Opiates | OPRK1, OPRM1, CYP2D6 | OPRM1 2/4885OPRD1 5/4885OPRK1 1/4885 |
| US-20190046523-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | OPRM1, OPRL1, OPRK1 | OPRM1 1/4885OPRD1 5/4885OPRK1 3/4885 |
| US-20070142628-A1 | 6-Monoacetylmorphine derivatives useful in immunoassay | OPRM1, MAG, IL6ST | OPRM1 1/4885OPRD1 67/4885OPRK1 24/4885 |
| US-20150112069-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | OPRM1, OPRL1, OPRK1 | OPRM1 1/4885OPRD1 5/4885OPRK1 3/4885 |
| US-20100041888-A1 | Process for the Preparation of 6-Alpha-Hydroxy-N-Alkylated Opiates | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885OPRD1 3/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.